ACS Medicinal Chemistry Letters · 2013 · 15 citations · 25 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLigand BindingPotency OptimizationStructure-activity Relationship AnalysisAggregationBinding Affinity AssessmentChemical Structure-activity RelationshipsCytotoxicity AssaysMedicinal HeterocyclesPhysicochemical PropertiesPlatelet Activation AssaysStructure - Activity Relationship Optimization
Octahydroindene was identified as a novel scaffold for protease activated receptor 1 (PAR1) antagonists. Herein, the 2-position (C2) was explored for structure-activity relationship (SAR) studies. Compounds 14, 19, and 23b showed IC50 values of 1.3, 8.6, and 2.7 nM in a PAR1 radioligand binding assay, respectively, and their inhibitory activities on platelet activation were comparable to that of vorapaxar in a platelet rich plasma (PRP) aggregation assay. This series of compounds showed high potency and no significant cytotoxicity; however, the compounds were metabolically unstable in both human and rat liver microsomes. Current research efforts are focused on optimizing the compounds to improve metabolic stability and physicochemical properties as well as potency.
25
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow, Eugene Braunwald, Marc P. Bonaca et al. · New England Journal of Medicine · 2012 · 941 citations · Full text
Domains specifying thrombin–receptor interaction
Thienkhai Vu, V I Wheaton, David T. Hung et al. · Nature · 1991 · 553 citations
High-resolution crystal structure of human protease-activated receptor 1
Cheng Zhang, Yoga Srinivasan, Daniel H. Arlow et al. · Nature · 2012 · 459 citations
Lutz Hein, Kenji Ishii, Shaun R. Coughlin et al. · Journal of Biological Chemistry · 1994 · 235 citations · Full text